At a glance
ClinicalIndex Comparison RecordN/ACompleted· 658 enrolled
Drug / intervention
JARDIANCE DUO®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE DUO® (Empagliflozin/Metformin, 5/500mg, 5/850mg, 5/1000mg, 12.5/500mg, 12.5/850mg, 12.5/1000mg) in Korean Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating JARDIANCE DUO® for Diabetes Mellitus, Type 2. Completed, enrolled 658 participants across 20 sites.
Detailed Summary
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionApr 2020
TodayJul 2026
First PostedAug 22, 2018
Enrollment StartAug 21, 2018
Primary CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.9 years ago
Interventions
JARDIANCE DUO®drug
empagliflozin and metformin